Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Atomoxetine in the treatment of ADHD symptoms in autistic children
IRCT20240925063160N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) and Autism Spectrum Disorder (ASD), sponsored by Urmia University of Medical Sciences. Started Nov 2024; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20240925063160N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240925063160N1.